http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#Head http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM http://www.nanopub.org/nschema#hasAssertion http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#assertion http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM http://www.nanopub.org/nschema#hasProvenance http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#provenance http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM http://www.nanopub.org/nschema#hasPublicationInfo http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#pubinfo http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#assertion http://resource.belframework.org/belframework/1.0/namespace/selventa-named-human-complexes/Nfkb%20Complex http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://amigo.geneontology.org/amigo/term/GO:0043234 http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#_1 http://semanticscience.org/resource/SIO_000139 http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#_2 http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#_1 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://amigo.geneontology.org/amigo/term/GO:0016301 http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#_2 http://purl.obolibrary.org/obo/RO_0002204 http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=5960 http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#_2 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080 http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#_3 http://semanticscience.org/resource/SIO_000139 http://resource.belframework.org/belframework/1.0/namespace/selventa-named-human-complexes/Nfkb%20Complex http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#_3 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://amigo.geneontology.org/amigo/term/GO:0042789 http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#_4 http://purl.obolibrary.org/obo/BFO_0000066 http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=9606 http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#_4 http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#_3 http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#_4 http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate http://www.selventa.com/vocabulary/increases http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#_4 http://www.w3.org/1999/02/22-rdf-syntax-ns#subject http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#_1 http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#_4 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#assertion http://www.w3.org/2000/01/rdf-schema#label kin(p(HGNC:IKBKB)) -> tscript(complex(NCH:"Nfkb Complex")) http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#provenance http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel http://purl.org/dc/elements/1.1/description Approximately 61,000 statements. http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel http://purl.org/dc/elements/1.1/rights Copyright (c) 2011-2012, Selventa. All rights reserved. http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel http://purl.org/dc/elements/1.1/title BEL Framework Large Corpus Document http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel http://purl.org/pav/authoredBy http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#_6 http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel http://purl.org/pav/version 1.4 http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#_5 http://www.w3.org/ns/prov#value Endocrine therapy with an estrogen receptor (ER)-targeted antiestrogen, such as tamoxifen, or estrogen ablation by aromatase inhibitors is clinically indicated for the management of all forms of ER-positive breast cancer. However, 30-50% of ER-positive breast cancer cases fail to benefit clinically from endocrine therapy alone, and recent molecular evidence suggests that 'crosstalk' pathways originating from activated receptor tyrosine kinases and/or other proliferative and survival signals may be contributing to this endocrine resistance. Molecular identification and validation of candidate ER crosstalking pathways will likely lead to clinically important prognostic markers and targets for the application of novel therapeutics in combination with standard endocrine agents. This review focuses on a critical survival and proliferation pathway involving activation of nuclear factor-kappaB (NFkappaB), a family of ubiquitously expressed transcription factors that for nearly two decades have been known to be critical regulators of mammalian immune and inflammatory responses, and more recently have been associated with chemotherapy resistance. With the demonstration that activation of NFkappaB is absolutely required for normal mammary gland development, NFkappaB involvment in human breast cancers was initially explored and linked to the development of hormone-independent (ER-negative) breast cancer. Newer clinical evidence now implicates NFkappaB activation, particularly DNA-binding by the p50 subunit of NFkappaB, as a potential prognostic marker capable of identifying a high-risk subset of ER-positive, primary breast cancers destined for early relapse despite adjuvant endocrine therapy with tamoxifen. Furthermore, initial preclinical studies suggest that treatment strategies designed to prevent or interrupt activation of NFkappaB in cell-line models of these more aggressive, ER-positive breast cancers can restore their sensitivity to such standard endocrine agents as tamoxifen. http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#_5 http://www.w3.org/ns/prov#wasQuotedFrom http://www.ncbi.nlm.nih.gov/pubmed/16113098 http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#_6 http://www.w3.org/2000/01/rdf-schema#label Selventa http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#assertion http://www.w3.org/ns/prov#hadPrimarySource http://www.ncbi.nlm.nih.gov/pubmed/16113098 http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#assertion http://www.w3.org/ns/prov#wasDerivedFrom http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#assertion http://www.w3.org/ns/prov#wasDerivedFrom http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#_5 http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM#pubinfo http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM http://purl.org/dc/terms/created 2014-07-03T14:30:37.694+02:00 http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM http://purl.org/pav/createdBy http://orcid.org/0000-0001-6818-334X http://www.tkuhn.ch/bel2nanopub/RAZqMvzBwRJpTEMajoWtUXKO9iEL8BMXX9hOOi8oYBDRM http://purl.org/pav/createdBy http://orcid.org/0000-0002-1267-0234